Novel ultrasensitive detection device for early Sepsis diagnosis
More than 27 M people per year develop sepsis, which has been catalogued as a Global health problem & priority. Sepsis kills more people than AIDs, prostate and breast cancer combined globally, and it lack of appropriate diagnosti...
ver más
MECWINS
La investigacion y desarrollo sobre ciencias naturales y tecnicas. el desarrollo, produccion y comercializacion de soluciones nanotecnologic...
TRL
4-5
| 390K€
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MuMiPOC
Multiparametric Microfluidic System for the Point Of Care de...
176K€
Cerrado
ASCMICROPLAT
Fast Automated Multiplex Analysis of Neonatal Sepsis Markers...
3M€
Cerrado
KlotoDx
KlotoDx A quick and cost effective near patient tool to iden...
71K€
Cerrado
ACUSEP
Integrated whole blood acoustophoresis and homogeneous nucle...
4M€
Cerrado
SepsISensoR
Sepsis Diagnosis via Integrated Breath Sensing System with C...
148K€
Cerrado
SMARTDIAGNOS
Next generation sepsis diagnosis
5M€
Cerrado
Información proyecto IVD4Sepsis
Duración del proyecto: 4 meses
Fecha Inicio: 2018-12-21
Fecha Fin: 2019-04-30
Líder del proyecto
MECWINS
La investigacion y desarrollo sobre ciencias naturales y tecnicas. el desarrollo, produccion y comercializacion de soluciones nanotecnologic...
TRL
4-5
| 390K€
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
More than 27 M people per year develop sepsis, which has been catalogued as a Global health problem & priority. Sepsis kills more people than AIDs, prostate and breast cancer combined globally, and it lack of appropriate diagnostic tools. Moreover it has been demonstrated that early detection during the first hours is crucial for survival.
Mecwins has developed the AVAC Technology prototype, an ultrasensitive detection equipment for early detection of sepsis, with: i) sensitivity a million times higher than current levels in clinical practice, ii) requiring smaller biological sample for the test, iii) multiplexing capability 30 biomarkers per analysis, iv) less diagnosis time ≤20 min, v) scalable solution - reference technology applicable to a wide range of other clinical applications (oncology, cardiovascular, autoimmune diseases, etc.).
The unique value proposition of AVAC Technology is based on the early, accurate and fast diagnosis of sepsis and its competitive price (30€ per test versus 150€ per test with PCR-Roche) compared to current techniques (PCR & ELISA).
Sepsis market is included on the infectious market and it was worth 278 M€ in 2015. Some estimations claim that it will grow until 717 M€ in 2021. Mecwins foresees to reach 25% of the total market by 2027 IVD4Sepsis through a double one-off revenue business model, and expecting a turnover accounting for almost 42,5 M€ by 2025.